JP7577682B2 - ガレクチン-3の低分子阻害剤 - Google Patents
ガレクチン-3の低分子阻害剤 Download PDFInfo
- Publication number
- JP7577682B2 JP7577682B2 JP2021559883A JP2021559883A JP7577682B2 JP 7577682 B2 JP7577682 B2 JP 7577682B2 JP 2021559883 A JP2021559883 A JP 2021559883A JP 2021559883 A JP2021559883 A JP 2021559883A JP 7577682 B2 JP7577682 B2 JP 7577682B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- diseases
- conditions
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831753P | 2019-04-10 | 2019-04-10 | |
| US62/831,753 | 2019-04-10 | ||
| PCT/US2020/027203 WO2020210308A1 (en) | 2019-04-10 | 2020-04-08 | Small molecule inhibitors of galectin-3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527395A JP2022527395A (ja) | 2022-06-01 |
| JP2022527395A5 JP2022527395A5 (cg-RX-API-DMAC10.html) | 2023-04-17 |
| JP7577682B2 true JP7577682B2 (ja) | 2024-11-05 |
Family
ID=70476468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559883A Active JP7577682B2 (ja) | 2019-04-10 | 2020-04-08 | ガレクチン-3の低分子阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12269819B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3953349A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7577682B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102890853B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN113710665A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020210308A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2021231243A1 (en) * | 2020-05-11 | 2021-11-18 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン-カルバモイル誘導体 |
| WO2022184755A1 (en) * | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018503660A (ja) | 2015-01-30 | 2018-02-08 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| WO2018209276A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2018209255A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| US9021050B2 (en) | 2012-08-31 | 2015-04-28 | Yume, Inc. | Network service system and method with off-heap caching |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (cg-RX-API-DMAC10.html) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| JP6844991B2 (ja) | 2015-11-10 | 2021-03-17 | サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスSanko Tekstil Isletmeleri San. Ve Tic. A.S. | ジッパーを有する伸縮性衣類の製法 |
-
2020
- 2020-04-08 US US17/601,942 patent/US12269819B2/en active Active
- 2020-04-08 KR KR1020217036227A patent/KR102890853B1/ko active Active
- 2020-04-08 WO PCT/US2020/027203 patent/WO2020210308A1/en not_active Ceased
- 2020-04-08 EP EP20722856.0A patent/EP3953349A1/en active Pending
- 2020-04-08 JP JP2021559883A patent/JP7577682B2/ja active Active
- 2020-04-08 CN CN202080027684.8A patent/CN113710665A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018503660A (ja) | 2015-01-30 | 2018-02-08 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| WO2018209276A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2018209255A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102890853B1 (ko) | 2025-11-24 |
| US20220144818A1 (en) | 2022-05-12 |
| US12269819B2 (en) | 2025-04-08 |
| KR20210150485A (ko) | 2021-12-10 |
| WO2020210308A1 (en) | 2020-10-15 |
| JP2022527395A (ja) | 2022-06-01 |
| EP3953349A1 (en) | 2022-02-16 |
| CN113710665A (zh) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527395A (ja) | ガレクチン-3の低分子阻害剤 | |
| JP6790183B2 (ja) | Ask1阻害剤の固体形態 | |
| CN114846005B (zh) | Shp2抑制剂及其应用 | |
| TWI657071B (zh) | 芳基醚及其用途 | |
| TWI912419B (zh) | 羥肟酸酯化合物、其製備方法及其應用 | |
| JP2021527106A (ja) | 新規化合物及び疾患の治療のためのその医薬組成物 | |
| WO2019211585A1 (en) | FACTOR XIIa INHIBITORS | |
| TWI891227B (zh) | 用於治療與apj受體活性相關的病狀的化合物及組成物 | |
| CN114423751A (zh) | 用作选择性aurora a抑制剂的新型杂环化合物 | |
| JP7478165B2 (ja) | ガレクチン-3の低分子阻害剤 | |
| CN107548389A (zh) | 环丙烷甲酸衍生物及其药学用途 | |
| JP7628348B2 (ja) | Tyk2阻害剤としてのヘテロアリール化合物、その組成物及び用途 | |
| CN112513041B (zh) | 三环化合物 | |
| JP7772718B2 (ja) | ガレクチン-3阻害剤 | |
| CN112312908A (zh) | Oga抑制剂化合物 | |
| JP7677995B2 (ja) | ガレクチン-3の低分子阻害剤 | |
| JP2025525481A (ja) | Tyk2/jak1の阻害剤としてのヘテロアリール化合物、その組成物および適用 | |
| HK40066473A (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| WO2025252235A1 (zh) | 一种用于调节β2整联蛋白的化合物及其药物组合物 | |
| HK40103849A (en) | 3,4-dihydro-2,7-naphthyridine1,6(2h,7h)-dione compounds as mek inhibitors | |
| JP2022511094A (ja) | ガレクチン-3の低分子阻害剤 | |
| HK40048874A (en) | Factor xiia inhibitors | |
| TW201444826A (zh) | 作爲raf激酶抑制劑的稠合三環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230407 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230407 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240307 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240701 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241015 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241023 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7577682 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |